UroGen Pharma Files 8-K
Ticker: URGN · Form: 8-K · Filed: Jan 14, 2025 · CIK: 1668243
| Field | Detail |
|---|---|
| Company | Urogen Pharma Ltd. (URGN) |
| Form Type | 8-K |
| Filed Date | Jan 14, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, regulatory-disclosure
Related Tickers: URGN
TL;DR
UroGen Pharma filed a routine 8-K, no major news.
AI Summary
UroGen Pharma Ltd. filed an 8-K on January 14, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain specific financial figures or material events beyond the standard reporting requirements.
Why It Matters
This filing indicates UroGen Pharma Ltd. is fulfilling its regular reporting obligations with the SEC, which is standard practice for publicly traded companies.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for reporting disclosures and exhibits, not indicating any specific new risks or material events.
Key Players & Entities
- UroGen Pharma Ltd. (company) — Registrant
- January 14, 2025 (date) — Date of earliest event reported
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report a Regulation FD Disclosure and to provide Financial Statements and Exhibits.
What is the exact date of the earliest event reported in this filing?
The date of the earliest event reported is January 14, 2025.
What is the company's central index key (CIK)?
The company's central index key (CIK) is 0001668243.
Where are UroGen Pharma Ltd.'s principal executive offices located?
UroGen Pharma Ltd.'s principal executive offices are located at 400 Alexander Park Drive, 4th Floor, Princeton, New Jersey, 08540.
What is the registrant's telephone number?
The registrant's telephone number, including area code, is +1 (646) 768-9780.
Filing Stats: 487 words · 2 min read · ~2 pages · Grade level 11.4 · Accepted 2025-01-14 07:01:05
Filing Documents
- d903812d8k.htm (8-K) — 25KB
- d903812dex991.htm (EX-99.1) — 46KB
- g903812ex99_1p10g1.jpg (GRAPHIC) — 350KB
- g903812ex99_1p11g1.jpg (GRAPHIC) — 344KB
- g903812ex99_1p12g1.jpg (GRAPHIC) — 196KB
- g903812ex99_1p13g1.jpg (GRAPHIC) — 342KB
- g903812ex99_1p14g1.jpg (GRAPHIC) — 328KB
- g903812ex99_1p15g1.jpg (GRAPHIC) — 293KB
- g903812ex99_1p16g1.jpg (GRAPHIC) — 289KB
- g903812ex99_1p17g1.jpg (GRAPHIC) — 214KB
- g903812ex99_1p18g1.jpg (GRAPHIC) — 281KB
- g903812ex99_1p19g1.jpg (GRAPHIC) — 290KB
- g903812ex99_1p1g1.jpg (GRAPHIC) — 357KB
- g903812ex99_1p20g1.jpg (GRAPHIC) — 263KB
- g903812ex99_1p21g1.jpg (GRAPHIC) — 247KB
- g903812ex99_1p22g1.jpg (GRAPHIC) — 210KB
- g903812ex99_1p23g1.jpg (GRAPHIC) — 200KB
- g903812ex99_1p24g1.jpg (GRAPHIC) — 384KB
- g903812ex99_1p25g1.jpg (GRAPHIC) — 375KB
- g903812ex99_1p26g1.jpg (GRAPHIC) — 216KB
- g903812ex99_1p27g1.jpg (GRAPHIC) — 225KB
- g903812ex99_1p28g1.jpg (GRAPHIC) — 229KB
- g903812ex99_1p29g1.jpg (GRAPHIC) — 159KB
- g903812ex99_1p2g1.jpg (GRAPHIC) — 620KB
- g903812ex99_1p30g1.jpg (GRAPHIC) — 281KB
- g903812ex99_1p31g1.jpg (GRAPHIC) — 250KB
- g903812ex99_1p32g1.jpg (GRAPHIC) — 385KB
- g903812ex99_1p33g1.jpg (GRAPHIC) — 246KB
- g903812ex99_1p34g1.jpg (GRAPHIC) — 339KB
- g903812ex99_1p35g1.jpg (GRAPHIC) — 360KB
- g903812ex99_1p36g1.jpg (GRAPHIC) — 222KB
- g903812ex99_1p37g1.jpg (GRAPHIC) — 250KB
- g903812ex99_1p38g1.jpg (GRAPHIC) — 257KB
- g903812ex99_1p39g1.jpg (GRAPHIC) — 343KB
- g903812ex99_1p3g1.jpg (GRAPHIC) — 298KB
- g903812ex99_1p40g1.jpg (GRAPHIC) — 230KB
- g903812ex99_1p41g1.jpg (GRAPHIC) — 81KB
- g903812ex99_1p42g1.jpg (GRAPHIC) — 242KB
- g903812ex99_1p43g1.jpg (GRAPHIC) — 289KB
- g903812ex99_1p44g1.jpg (GRAPHIC) — 351KB
- g903812ex99_1p4g1.jpg (GRAPHIC) — 261KB
- g903812ex99_1p5g1.jpg (GRAPHIC) — 297KB
- g903812ex99_1p6g1.jpg (GRAPHIC) — 350KB
- g903812ex99_1p7g1.jpg (GRAPHIC) — 345KB
- g903812ex99_1p8g1.jpg (GRAPHIC) — 282KB
- g903812ex99_1p9g1.jpg (GRAPHIC) — 283KB
- 0001193125-25-005649.txt ( ) — 17645KB
- urgn-20250114.xsd (EX-101.SCH) — 3KB
- urgn-20250114_lab.xml (EX-101.LAB) — 18KB
- urgn-20250114_pre.xml (EX-101.PRE) — 11KB
- d903812d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibit No. Description 99.1 Company Presentation, dated January 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: January 14, 2025 UROGEN PHARMA LTD. By: /s/ Chris Degnan Chris Degnan Chief Financial Officer